SINUVA, a Corticosteroid Releasing Sinus Implant, Now Available for Nasal Polyps
Intersect ENT, based in Menlo Park, California, is releasing in the U.S. its SINUVA sinus implant for treating nasal polyp disease in adults that underwent previous surgical sinus procedures. The device elutes mometasone furoate, a corticosteroid, to reduce inflammation directly at the polyps. The drug is released for approximately 90 days after the SINUVA is implanted in an in-office procedure.
“After years of development and multiple clinical studies, we are thrilled to provide physicians with SINUVA to treat patients with nasal polyps. SINUVA offers an alternative to patients who have exhausted routine medical m...
Source: Medgadget - April 9, 2018 Category: Medical Devices Authors: Editors Tags: ENT Source Type: blogs
Don ’t let allergy season catch you off guard
The woman next to me in the checkout line looked upset. Her eyes were red and her nose was running. My first thought was to give her privacy, until I saw her shopping basket filled with supplies to fight allergy symptoms, and then our eyes met. “I can’t believe how bad my allergies are this year!” she said, exasperated.
My fellow shopper isn’t the only one suffering. “Warm weather and a mild winter, as we’ve experienced this year, can stimulate trees to pollinate. The southern U.S., which has a warmer climate, is particularly susceptible to earlier allergy seasons. Other climate factors — such as cool evening...
Source: Harvard Health Blog - April 6, 2017 Category: Consumer Health News Authors: Heidi Godman Tags: Asthma and Allergies Source Type: blogs
Strengthen Medicare: End Drug Company Price Setting
It’s no secret that, four years ago, President Obama cut a deal with the pharmaceutical industry. He promised that so long as the drug companies did not block health reform, federal law would continue to prohibit Medicare from negotiating drug prices. Instead, the pharmaceutical industry would get 30 million new customers and remain free to set drug prices for Americans. This single policy will cost Medicare and U.S. tax payers hundreds of billions of dollars over the next ten years.
If Congress wants to contain long-term Medicare spending and keep health care affordable in America, lawmakers should start with the low-...
Source: Health Affairs Blog - May 28, 2013 Category: Health Medicine and Bioethics Commentators Authors: Diane Archer Tags: All Categories Health Care Costs Medicaid Medicare Pharma Policy Spending Source Type: blogs
